Interim Management Statement

FINSBURY WORLDWIDE PHARMACEUTICAL TRUST PLC                  

    Interim Management Statement - 3 months to 31 December 2009 (unaudited)    

Finsbury Worldwide Pharmaceutical Trust PLC invests worldwide in pharmaceutical
, biotechnology and related companies in the healthcare sector with the 
objective of achieving a high level of capital growth.

During the 3 month period ending 31 December 2009 the Company's undiluted net
asset value per share rose by 2.7% and the share price by 4.0%, compared to a
rise of 4.7% in the Company's benchmark, the DataStream World Pharmaceutical
and Biotechnology Index measured in sterling terms on a total return basis.
This performance was achieved against a background of a depreciating US$
against sterling. The exchange rate at 30 September 2009 was 1.5994 compared to
1.6149 at 31 December 2009, a movement of 1%.

During the three-month period a total of 2,836,033 shares were repurchased to
be held in treasury. Since the period end, to 15 February 2010, a further
818,311 shares have been bought back for treasury. The shares repurchased
during the period and up to 15 February 2010 were done so at a cost of £21.6m
(including expenses).

In the period from 31 December 2009 to 15 February 2010, the Company's diluted
net asset value per share and the share price both rose by 5.2% and 1.9%
respectively compared to a rise of 1.8% in the Company's benchmark, all
measured on a total return basis.

The Company allotted 9,730,960 new subscription shares on 4 September 2009;
such subscription shares having quarterly subscription dates. On the first two
subscription dates, being 31 October 2009 and 1 February 2010, a total of
738,653 subscription shares were converted into ordinary shares raising £4.5m.

The Company will be renewing its share buy-back authority at a General Meeting
to be held on 2 March 2010.

Trust Characteristics

                           31 December 2009          30 September 2009         
                                                                               
Number of holdings         48                        49                        
                                                                               
Net assets (£m)            297.9                     308.0                     
                                                                               
Net yield                  0.8%                      0.8%                      
                                                                               
Gearing (AIC basis)        111                       105                       
                                                                               
Share price (p)            616.00                    592.50                    
                                                                               
NAV (p) -undiluted         660.00                    642.72                    
                                                                               
NAV (p) diluted: sub       651.87                    637.87                    
shares                                                                         
                                                                               
NAV (p) - fully diluted    649.01                    636.42                    
for                                                                            
                                                                               
sub shares and treasury                                                        
shares                                                                         
                                                                               
(Discount)/premium         (6.7%)                    (7.8%)                    
(undiluted)                                                                    
                                                                               
(Discount/premium(diluted  (5.5%)                    (7.1%)                    
- sub shares)                                                                  
                                                                               
(Discount/premium (fully   (5.1%)                    (6.9%)                    
diluted)                                                                       
                                                                               
Subscription share price   56.50                     62.25                     
(p)                                                                            

Source: Frostrow Capital LLP

10 Largest Investments

Name                                 % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                              at 31 December 2009       at 30 September 2009   
                                                                               
Roche                                 7.9                       7.5            
                                                                               
Johnson & Johnson                     7.5                       7.1            
                                                                               
Novartis                              7.4                       6.8            
                                                                               
Amgen                                 4.3                       3.1            
                                                                               
Bristol-Myers Squibb                  3.8                       3.4            
                                                                               
Dendreon                              3.4                       2.0            
                                                                               
Sinopharm                             3.0                       1.4            
                                                                               
Shire                                 3.0                       2.7            
                                                                               
Genzyme                               2.8                       3.3            
                                                                               
Teva Pharmaceutical                   2.7                       2.5            
                                                                               
                                     45.8                       39.8           

Source: Frostrow Capital LLP

Sector Analysis

                                     % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                              at 31 December 2009       at 30 September 2009   
                                                                               
Large capitalisation                 59.5                       65.5           
                                                                               
Small capitalisation                 40.5                       34.5           
                                                                               
Total                                100.0                     100.0           

Source: Frostrow Capital LLP

Geographical Analysis

                                     % of                       % of           
                                                                               
                                  portfolio                  portfolio         
                                                                               
                             at 31 December 2009        at 30 September 2009   
                                                                               
North America                        65.7                       65.2           
                                                                               
Europe                               22.8                       22.9           
                                                                               
Israel                               2.7                        2.5            
                                                                               
Far East                             8.8                        9.4            
                                                                               
Total                               100.0                      100.0           

Source: Frostrow Capital LLP

Total Return Performance

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     +4.0%           +11.1%          +29.7%          +41.7%         
                                                                               
NAV Fully       +2.0%           +6.8%           +29.9%          +45.0%         
diluted                                                                        
                                                                               
Benchmark*      +4.7%           +4.2%           +24.1%          +50.7%         

Source: NAV (total return; fully diluted) and Share Price (total return)
Morningstar. Benchmark - Thomson Financial Ltd.

* Benchmark - Datastream World Pharmaceutical and Biotechnology Index measured
in sterling terms on a total return basis.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.finsburywp.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com

SEDOL Codes:

Shares - 0338530

Subscription Shares - B3VMCB0

ISIN -

Shares - GB0003385308

Subscription Shares - GB00B3VMCB07

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

17 February 2010